LEGN,RARE,ONC Stock Price and Quote

Peers: INCY IONS ALNY BMRN KYMR CRNX KRYS VRTX REGN BIIB

| Held by: IBB IEMG PBE CANC EEM MCHI IXUS IXUS GNOM SPEM

Index	-
Market Cap	3.57B
Enterprise Value	2.89B
Income	-91.90M
Sales	1.27B
Book/sh	6.35
Cash/sh	4.98
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	2900
IPO	Jun 05, 2020

P/E	-
Forward P/E	31.13
PEG	-
P/S	2.80
P/B	2.91
P/C	3.70
P/FCF	-
EV/EBITDA	-
EV/Sales	2.26
Quick Ratio	2.94
Current Ratio	3.04
Debt/Eq	0.23
LT Debt/Eq	0.09
Option/Short	Yes / Yes

EPS (ttm)	-0.51
EPS next Y	0.59
EPS next Q	0.00
EPS this Y	95.86%
EPS next Y	1865.95%
EPS next 5Y	-
EPS past 3/5Y	16.80% 6.49%
Sales past 3/5Y	106.67% 68.87%
EPS Y/Y TTM	71.96%
Sales Y/Y TTM	59.59%
EPS Q/Q	125.11%
Sales Q/Q	51.64%
Earnings	Aug 11 BMO
EPS/Sales Surpr.	59.86% 8.86%

Insider Own	4.63%
Insider Trans	-0.43%
Inst Own	50.99%
Inst Trans	3.54%
ROA	-5.34%
ROE	-8.11%
ROIC	-6.86%
Gross Margin	53.00%
Oper. Margin	-4.12%
Profit Margin	-7.21%
SMA20	-1.41%
SMA50	-6.72%
SMA200	-17.64%
Trades

Shs Outstand	193.77M
Shs Float	184.80M
Short Float	7.92%
Short Ratio	6.25
Short Interest	14.64M
52W High	37.50 -50.83%
52W Low	16.24 13.55%
Volatility	4.44% 4.47%
ATR (14)	0.89
RSI (14)	43.17
Beta	0.57
Rel Volume	0.64
Avg Volume	2.34M
Volume	187,499

Perf Week	-0.97%
Perf Month	-15.22%
Perf Quarter	-33.38%
Perf Half Y	-1.28%
Perf YTD	-15.18%
Perf Year	-42.48%
Perf 3Y	-71.87%
Perf 5Y	-64.69%
Perf 10Y	-
Recom	1.71
Target Price	46.38
Prev Close	18.57
Price	18.44
Change %	-0.70%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-12-26	Downgrade	Oppenheimer	Outperform → Perform
Jul-24-26	Downgrade	UBS	Buy → Neutral	$28
Jul-13-26	Resumed	JP Morgan	Neutral	$35
Feb-12-26	Downgrade	Rothschild & Co Redburn	Buy → Neutral	$24
Jan-22-26	Downgrade	TD Cowen	Buy → Hold	$21
Jan-07-26	Initiated	Oppenheimer	Outperform	$75
Oct-07-25	Initiated	Cantor Fitzgerald	Overweight	$40
Oct-08-24	Initiated	Redburn Atlantic	Buy	$86
Jun-17-24	Initiated	Truist	Buy	$88
May-24-24	Reiterated	H.C. Wainwright	Buy	$86 → $73
May-23-24	Initiated	Deutsche Bank	Buy	$60
Apr-17-24	Upgrade	Scotiabank	Sector Perform → Sector Outperform	$65
Apr-03-24	Initiated	Cantor Fitzgerald	Overweight	$82
Mar-13-24	Initiated	Raymond James	Outperform	$86
Dec-19-23	Initiated	Scotiabank	Sector Perform
Nov-06-23	Initiated	Goldman	Buy	$90.09
May-25-23	Initiated	William Blair	Mkt Perform	$64
May-22-23	Initiated	Daiwa Securities	Buy
Mar-29-23	Initiated	H.C. Wainwright	Buy	$66
Mar-24-23	Initiated	RBC Capital Mkts	Outperform	$73

Show Previous Ratings

Oct-01-26 09:00AM	Legend Biotech Launches Inaugural ELITE Grant Program to Advance the Next Generation of CAR-T Innovation in Multiple Myeloma (GlobeNewswire)
Sep-25-26 07:00AM	Legend Biotech Presents CARVYKTI Data Showing Half of Patients with RRMM Remained Progression-Free and Alive Five Years After a Single Infusion (GlobeNewswire)
Sep-15-26 07:40PM	LEGNs New CEO From Novartis Paves Way For Buyout Speculation (Stocktwits)
08:00AM	Legend Biotech Appoints Ingrid Zhang as Chief Executive Officer (GlobeNewswire)
07:30AM	Legend Naming Novartis Executive as CEO (The Wall Street Journal)
08:00AM	Loading…
Sep-10-26 08:00AM	Legend Biotech to Present Updated Long-Term and Real-World Evidence from CARVYKTI Clinical Program at the International Myeloma Society Annual Meeting (GlobeNewswire)
Sep-01-26 08:00AM	Legend Biotech to Participate in the Morgan Stanley Global Healthcare Conference (GlobeNewswire)
05:08AM	The hidden scale-out problem behind CAR-Ts growth (Pharma Voice)
Aug-11-26 03:00PM	Legend Biotech Corp (LEGN) (Q2 2026) Earnings Call Highlights: First Profitable Quarter Driven ... (GuruFocus.com) +5.66%
10:25AM	Legend Biotech shares rise 5% as Q2 earnings and revenue beat estimates (InvestorsHub)
08:12AM	Ex-Legend CEO takes helm at biotech startup scouring the globe for drugs (BioPharma Dive)
07:00AM	Legend Biotech Reports Second Quarter 2026 Results and Recent Highlights (GlobeNewswire)
Jul-28-26 11:35AM	Leadership changes afoot at two CGT biotechs (Pharmaceutical Technology)
08:00AM	Legend Biotech to Host Investor Conference Call on Second Quarter 2026 Results (GlobeNewswire)
Jul-27-26 02:35PM	LEGN Stock Plunges 15% After Sudden CEO Exit But Analyst Reiterates Optimism In Companys Under-Development Lymphoma Asset (Stocktwits) -13.28%
01:01PM	Loading…
01:01PM	?? Under the Radar: Legend Stock Tumbles After CEO's Abrupt Departure (The Wall Street Journal)
07:00AM	FDA scientists question Capricor data; Legend CEO steps down (BioPharma Dive)
06:00AM	Legend Biotech Announces CEO Transition (GlobeNewswire)
Jun-17-26 09:21PM	Legend Biotech Corporation Announces Pricing of Public Offering (GlobeNewswire) -16.68%
04:29PM	Legend Biotech Corporation Announces Proposed Public Offering (GlobeNewswire)
Jun-15-26 08:00AM	Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (GlobeNewswire)
Jun-14-26 03:15AM	Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (GlobeNewswire)
Jun-11-26 03:56PM	Imviva Unveils Leukemia Data at EHA 2026 With 86% Response Rates (Exec Edge)
Jun-03-26 07:57AM	Legend surges on early data for in vivo lymphoma cell therapy (BioPharma Dive)
Jun-02-26 11:28AM	ASCO 2026: Mixed SCLC result for Legends LB2102, Novartis expedites manufacture (Pharmaceutical Technology) +42.22%
09:38AM	Legend's Cancer-Fighter Notches Elusive 100% Success Rate; What's Next? (Investor's Business Daily)
09:30AM	Legend Biotech Announces Late-Breaking Oral Presentation at EHA 2026 Showcasing Initial Phase 1 In Vivo CAR-T Data with LB2501 in Non-Hodgkin Lymphoma (NHL) (GlobeNewswire)
Jun-01-26 10:00AM	Legend Biotech Presents First-in-Human LB2102 Results in Solid Tumors and New CARVYKTI Data in Multiple Myeloma at ASCO 2026 (GlobeNewswire) -6.08%
May-28-26 12:30PM	J&J's Strategy for Deals on the Cheap Faces a Big Test (The Wall Street Journal)
05:30AM	J&J Mastered Cancer Biotech Deals on the Cheap. Can It Stay on the Cutting Edge? (The Wall Street Journal)
05:00PM	Loading…
May-21-26 05:00PM	Legend Biotech Announces Presentations at ASCO 2026 (GlobeNewswire)
May-12-26 03:00PM	Legend Biotech Corp (LEGN) Q1 2026 Earnings Call Highlights: Strong CARVYKTI Sales and ... (GuruFocus.com) +10.48%
07:00AM	Legend Biotech Reports First Quarter 2026 Results and Recent Highlights (GlobeNewswire)
May-04-26 08:00AM	Legend Biotech Expands Scientific Advisory Expertise to Inform Future Growth (GlobeNewswire) +12.34%
Apr-28-26 08:00AM	Legend Biotech to Host Investor Conference Call on First Quarter 2026 Results (GlobeNewswire)
Mar-25-26 01:10PM	Johnson & Johnson Exits 3 Biotechs but Keeps Stakes in These Rumored Acquisition Targets (Barrons.com)
Mar-16-26 03:00AM	Genscript Biotech Corp (GNNSF) Full Year 2025 Earnings Call Highlights: Record Revenue Growth ... (GuruFocus.com)
Mar-10-26 03:00PM	Legend Biotech Corp (LEGN) Q4 2025 Earnings Call Highlights: Record Growth and Profitability ... (GuruFocus.com)
07:00AM	Legend Biotech Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights (GlobeNewswire)
Feb-24-26 08:00AM	Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2025 Results (GlobeNewswire)
Feb-18-26 02:04AM	Barclays Cite Favorable Long-Term Outlook For Legend Biotech Corporation (LEGN) Despite Near-Term Expectation Revisions (Insider Monkey)
Feb-16-26 12:24PM	FDA Guidance on MRD Negativity Bodes Well for Legend Biotech (LEGN) (Insider Monkey)
Feb-07-26 03:33AM	Legend Biotech (LEGN) Shakes Up Board (Insider Monkey)
Feb-02-26 09:38AM	H.C. Wainwright Highlight Curative Potential of Legend Biotech Corporation (LEGN)'s Carvykti Despite Sales Miss (Insider Monkey)
Jan-26-26 03:14AM	Legend Biotech (LEGN) Advances Cell Therapy Innovation and Expands Oncology Pipeline (Insider Monkey)
Jan-22-26 08:00AM	Here Are Thursdays Top Wall Street Analyst Research Calls: Alphabet, Callaway Golf, Datadog, Hyatt Hotels, Palantir, Texas Instruments, Verizon, and More (24/7 Wall St.) -6.84%
Jan-21-26 08:00AM	Legend Biotech to Present CARVYKTI Data at 2026 Tandem Meetings Reinforcing Growing Evidence Supporting Earlier Use (GlobeNewswire) -11.36%
Jan-12-26 08:00AM	Legend Biotech Highlights Recent Business Updates at 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-09-26 03:16AM	Cantor Fitzgerald and RBC Capital Stay Bullish on Legend Biotech (LEGN) (Insider Monkey)
Dec-22-25 06:50AM	Here is Why Legend Biotech (LEGN) Offers Such Promising Upside (Insider Monkey)
Dec-17-25 08:00AM	Legend Biotech to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-11-25 07:44AM	Legend Biotech Corporation (LEGN) is an Outperform on Multiple Myeloma Treatment CARVYKTI Prospects (Insider Monkey)
Dec-09-25 03:31PM	Cancer Study Buoys These Small Biotechs (Barrons.com) -8.58%
Dec-06-25 02:00PM	Legend Biotech Highlights New CARVYKTI Data in Multiple Myeloma and First-in-Human Results from Novel CAR-T Platform in Non-Hodgkin Lymphoma at ASH 2025 (GlobeNewswire)
Nov-27-25 09:00AM	Legend Biotech Awarded 2025 FIBA Foreign Investor of the Year by Flanders Investment & Trade (GlobeNewswire)
Nov-25-25 08:39AM	William Blair Maintains Hold Rating on Legend Biotech (LEGN) Despite Carvykti Label Safety Concerns (Insider Monkey)
Nov-13-25 12:08PM	Legend Biotech Celebrates Official Opening of New State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia (GlobeNewswire)
09:21AM	Company News for Nov 13, 2025 (Zacks)
Nov-12-25 02:03PM	Legend Biotech Corp (LEGN) Q3 2025 Earnings Call Highlights: Record CARVYKTI Sales and ... (GuruFocus.com)
07:00AM	Legend Biotech Reports Third Quarter 2025 Results and Recent Highlights (GlobeNewswire)
Nov-10-25 08:16PM	H.C. Wainwright Remains Bullish on Legend Biotech (LEGN), Cites Solid Growth Trajectory for CARVYKTI Therapy (Insider Monkey)
Nov-03-25 11:05AM	Legend Biotech Announces 10 Presentations at the 67th American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Oct-29-25 08:00AM	Legend Biotech to Host Investor Conference Call on Third Quarter 2025 Results (GlobeNewswire)
Oct-21-25 09:15AM	CorMedix (CRMD) Surges 19.5%: Is This an Indication of Further Gains? (Zacks)
Oct-17-25 09:54PM	J.P. Morgan Maintains a Buy on Legend Biotech Corporation (LEGN) (Insider Monkey)
Oct-08-25 12:57AM	TD Cowen Reiterates a Buy Rating on Legend Biotech Corporation (LEGN) (Insider Monkey)
Sep-30-25 04:00AM	RBC Capital Reiterates a Buy Rating on Legend Biotech Corporation (LEGN) (Insider Monkey)
Aug-26-25 08:00AM	Legend Biotech to Participate in the Morgan Stanley Global Healthcare Conference (GlobeNewswire)
Aug-22-25 11:57PM	RBC Capital Lifts PT on Legend Biotech Corporation (LEGN) to $77 From $75 (Insider Monkey)
05:30AM	China's rise in biotech to potentially lower healthcare costs, life science investor says (South China Morning Post)
Aug-18-25 08:00AM	Legend Biotech Appoints Carlos Santos as Chief Financial Officer (GlobeNewswire)
Aug-12-25 07:22AM	Company News for Aug 12, 2025 (Zacks)
03:03AM	Legend Biotech Corp (LEGN) Q2 2025 Earnings Call Highlights: Record CARVYKTI Sales and ... (GuruFocus.com)
Aug-11-25 10:53AM	Key Inflation Data in Focus (Zacks)
10:12AM	Pre-Markets in Green, Inflation Data, Retail Sales, Q2 Earnings This Week (Zacks)
07:00AM	Legend Biotech Reports Second Quarter 2025 Results and Recent Highlights (GlobeNewswire)
Aug-08-25 09:17AM	Legend Biotech Corp (LEGN) Q2 2025 Earnings Report Preview: What to Expect (GuruFocus.com)
Jul-28-25 08:00AM	Legend Biotech to Host Investor Conference Call on Second Quarter 2025 Results (GlobeNewswire)
Jul-18-25 07:24AM	Legend Biotech (LEGN) Surges 6.0%: Is This an Indication of Further Gains? (Zacks)
Jul-13-25 05:00PM	China Biotechs Stunning Advance Is Changing the Worlds Drug Pipeline (Bloomberg)
Jul-06-25 04:15AM	H.C. Wainwright Maintains a Buy on Legend Biotech (LEGN) With a $75 Price Target (Insider Monkey)
Jun-20-25 04:08PM	The FDA Shake-Up Continues, And Could Impact Genetic Medicines (Investor's Business Daily)
Jun-03-25 10:45AM	Legend Biotech Unveils Groundbreaking 5-Year Survival Data for CARVYKTI in Multiple Myeloma at 2025 ASCO Annual Meeting (GlobeNewswire)
May-22-25 05:15PM	Legend Biotech Announces New Oncologic & Hematologic Therapeutic Developments at ASCO, EHA, and ASGCT (GlobeNewswire)
May-19-25 08:00AM	Legend Biotech to Host Investor Event During the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
May-14-25 09:18AM	Morning Movers: UnitedHealth sinks following CEO exit and outlook suspension (TipRanks) -10.55%
03:06AM	Legend Biotech Corp (LEGN) Q1 2025 Earnings Call Highlights: Record Growth in CARVYKTI Sales ... (GuruFocus.com)
12:24AM	Q1 2025 Legend Biotech Corp Earnings Call (Thomson Reuters StreetEvents)
May-13-25 07:00AM	Legend Biotech Reports First Quarter 2025 Results and Recent Highlights (GlobeNewswire)
May-12-25 09:20AM	What To Expect From Legend Biotech Corp (LEGN) Q1 2025 Earnings (GuruFocus.com)
May-03-25 04:51AM	The Play On Legend Biotech (Seeking Alpha)
May-02-25 12:00PM	What Makes Legend Biotech (LEGN) a New Buy Stock (Zacks)
09:55AM	Wall Street Analysts Think Legend Biotech (LEGN) Could Surge 135.16%: Read This Before Placing a Bet (Zacks)
Apr-29-25 08:00AM	Legend Biotech to Host Investor Conference Call on First Quarter 2025 Results (GlobeNewswire)
Apr-24-25 06:53AM	Legend Biotech Corporation (LEGN): Among Takeover Rumors Hedge Funds Are Buying (Insider Monkey)
Apr-16-25 09:53AM	Legend Biotech (LEGN) Moves 5.1% Higher: Will This Strength Last? (Zacks)
Apr-11-25 12:30AM	Harbor Health Care ETF Q4 2024 Commentary (Seeking Alpha)
Apr-09-25 05:53AM	Pacira (PCRX) Surges 14.7%: Is This an Indication of Further Gains? (Zacks)
Apr-01-25 11:50AM	Biotech stocks slide as Marks resignation seen being negative for sector (TipRanks) -7.10%
Mar-12-25 03:02AM	Legend Biotech Corp (LEGN) Q4 2024 Earnings Call Highlights: Record CARVYKTI Sales and ... (GuruFocus.com)

Legend Biotech Corp. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, manufacturing, and commercialization of novel therapies for oncology and other indications. The firm develops advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell, gamma-delta T cell and natural killer cell-based immunotherapy. It operates through the following geographical segments: United States of America, China, and Other. The company was founded in 2014 and is headquartered in Somerset, NJ.

Chief Executive OfficerMs. Ingrid Zhang

Chief Financial OfficerMr. Carlos Santos Garcia

J.D.Ms. Ananda Elizabeth Martin Esq.

General CounselMr. Robert Staloff

Interim Head of Research & Development and Senior VP of Regulatory AffairsDr. Yuhong Qiu Ph.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Sanders Corazon (Corsee) D.	Director	Sep 29 '26	Sale	9.46	27,370	258,920	52,731	Oct 01 04:04 PM
Sanders Corazon (Corsee) D.	Director	Sep 29 '26	Proposed Sale	18.92	13,685	258,915		Sep 29 02:31 PM
Santos Carlos E	Chief Financial Officer	Sep 21 '26	Sale	9.14	5,430	49,630	14,246	Sep 23 04:15 PM
Santos Carlos E	Officer	Sep 22 '26	Proposed Sale	18.73	2,715	50,854		Sep 22 03:30 PM
Huang Ying	Former Officer & Director	Sep 22 '26	Proposed Sale	18.65	69,812	1,302,109		Sep 22 02:33 PM
Casey Patrick John	Director	Jun 30 '26	Proposed Sale	29.60	3,000	88,800		Jun 30 10:46 AM
Huang Ying	Chief Executive Officer	Jun 25 '26	Sale	14.78	5,566	82,265	241,872	Jun 29 09:53 PM
Huang Ying	Officer	Jun 26 '26	Proposed Sale	28.39	2,783	79,017		Jun 26 03:23 PM
Huang Ying	Chief Executive Officer	Mar 25 '26	Sale	8.77	9,936	87,139	247,438	Mar 27 04:25 PM
Huang Ying	Officer	Mar 26 '26	Proposed Sale	17.54	4,968	87,149		Mar 26 04:27 PM
Yeung Jessie	Officer	Mar 26 '26	Proposed Sale	17.54	1,862	32,663		Mar 26 04:20 PM
Huang Ying	Officer	Dec 26 '25	Proposed Sale	22.52	64,339	1,449,074		Dec 29 07:28 AM
Sanders Corazon (Corsee) D.	Director	Dec 24 '25	Proposed Sale	22.77	969	22,064		Dec 29 06:45 AM
Huang Ying	Officer	Dec 24 '25	Proposed Sale	22.95	61,467	1,410,606		Dec 29 06:40 AM
GenScript Corporation	Affiliate	Nov 17 '25	Proposed Sale	30.29	203,586	6,166,620		Nov 17 05:50 PM

RARE Ultragenyx Pharmaceutical Inc daily Stock Chart

Peers: BMRN RYTM KRYS MIRM PTCT IONS ALNY KOD INCY VRTX

| Held by: VTI XBI VB IWM VBK VXF VTWO IBB SCHA IWN

Index	RUT
Market Cap	1.47B
Enterprise Value	2.38B
Income	-586.41M
Sales	716.93M
Book/sh	-2.96
Cash/sh	3.05
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	1371
IPO	Jan 31, 2014

P/E	-
Forward P/E	-
PEG	-
P/S	2.05
P/B	-
P/C	4.89
P/FCF	-
EV/EBITDA	-
EV/Sales	3.32
Quick Ratio	1.56
Current Ratio	1.73
Debt/Eq	-
LT Debt/Eq	-
Option/Short	Yes / Yes

EPS (ttm)	-5.84
EPS next Y	-0.31
EPS next Q	-0.93
EPS this Y	32.04%
EPS next Y	92.29%
EPS next 5Y	-
EPS past 3/5Y	16.78% -13.72%
Sales past 3/5Y	22.81% 19.95%
EPS Y/Y TTM	-5.66%
Sales Y/Y TTM	17.50%
EPS Q/Q	22.67%
Sales Q/Q	28.53%
Earnings	Aug 04 AMC
EPS/Sales Surpr.	26.08% 16.89%

Insider Own	8.79%
Insider Trans	-0.37%
Inst Own	105.33%
Inst Trans	1.19%
ROA	-45.63%
ROE	-656.54%
ROIC	-70.23%
Gross Margin	78.47%
Oper. Margin	-73.77%
Profit Margin	-81.79%
SMA20	2.71%
SMA50	-28.78%
SMA200	-37.80%
Trades

Shs Outstand	98.30M
Shs Float	89.92M
Short Float	18.43%
Short Ratio	4.42
Short Interest	16.57M
52W High	39.89 -62.60%
52W Low	12.73 17.20%
Volatility	5.08% 5.80%
ATR (14)	1.07
RSI (14)	37.20
Beta	0.38
Rel Volume	0.46
Avg Volume	3.75M
Volume	215,489

Perf Week	3.54%
Perf Month	0.47%
Perf Quarter	-58.41%
Perf Half Y	-34.76%
Perf YTD	-35.13%
Perf Year	-52.19%
Perf 3Y	-57.33%
Perf 5Y	-82.87%
Perf 10Y	-79.52%
Recom	2.00
Target Price	26.79
Prev Close	15.22
Price	14.92
Change %	-1.97%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-03-26	Downgrade	William Blair	Outperform → Mkt Perform
Sep-03-26	Downgrade	Wells Fargo	Overweight → Equal Weight	$18
Sep-03-26	Downgrade	Robert W. Baird	Outperform → Neutral	$16
Sep-03-26	Downgrade	JP Morgan	Overweight → Neutral	$36
Sep-03-26	Downgrade	Evercore ISI	Outperform → In-line	$16
Sep-03-26	Downgrade	BofA Securities	Buy → Neutral
Mar-24-26	Downgrade	Goldman	Buy → Neutral	$25
Oct-20-25	Initiated	Wells Fargo	Overweight	$65
Jul-28-25	Resumed	H.C. Wainwright	Buy	$80
May-28-25	Initiated	William Blair	Outperform
Jun-06-24	Upgrade	Goldman	Neutral → Buy	$56 → $67
Apr-22-24	Initiated	RBC Capital Mkts	Outperform	$77
Dec-08-23	Initiated	Wells Fargo	Overweight	$72
Jun-14-23	Resumed	Credit Suisse	Outperform	$96
Jun-06-23	Upgrade	Evercore ISI	In-line → Outperform	$60 → $80
Apr-26-23	Initiated	Cantor Fitzgerald	Overweight	$114
Jan-18-23	Resumed	Canaccord Genuity	Buy	$90
Dec-30-22	Resumed	H.C. Wainwright	Buy	$82
Nov-03-22	Upgrade	Robert W. Baird	Neutral → Outperform	$50
Oct-13-22	Upgrade	Guggenheim	Neutral → Buy	$50

Show Previous Ratings

Oct-02-26 02:00AM	Ultragenyx Announces Marketing Authorisation Application (MAA) Submission to the European Medicines Agency (EMA) for the First Investigational Gene Therapy for MPS IIIA (Sanfilippo Syndrome Type A) (GlobeNewswire)
Sep-22-26 03:09PM	RARE Stock Climbs This Week As Investors Look Past Trial Failure To Gene Therapy Launches, Trial Results (Stocktwits) +6.59%
Sep-18-26 08:16AM	Ultragenyx Gets A Much-Needed Win, Says Cantor Sees $400M Opportunity After FDA Approves Neurodegenerative Disease Therapy (Stocktwits)
06:24AM	Ultragenyx prices Sanfilippo gene therapy at $4M; Bristol Myers shelves Orum drug (BioPharma Dive)
Sep-17-26 07:33PM	ABEO Stock Gains On Approval For A Drug Abeona Sold, Rating For The One It Sells (Stocktwits) +12.58%
06:36PM	Loading…
06:36PM	RARE Stock Jumps 13% Extends Gains After-Hours As FDA Clears First Sanfilippo Gene Therapy (Stocktwits)
03:54PM	Ultragenyx Stock Jumps on Landmark FDA Approval (Barrons.com)
03:48PM	Ultragenyx Announces Approval of FAYUVI Gene Therapy, the First-Ever FDA-Approved Treatment for Sanfilippo Syndrome Type A (MPS IIIA) (GlobeNewswire)
Sep-16-26 03:38PM	RARE Stock Hits Fresh 52-Week Low As Sanfilippo Drug Ruling Nears Failed Angelman Syndrome Trial Weighs On Shares (Stocktwits)
Sep-15-26 09:51PM	Biotech Midweek Pulse: XBI Loses Steam After Hot 2026 Run Here Are The Stocks And Catalysts To Watch Next (Stocktwits)
Sep-04-26 03:24AM	RARE Stock Crashes In Worst Day Ever Pharma Bro Martin Shkreli Calls It Very Cheap, Floats BioMarin Buyout (Stocktwits)
12:22AM	Why Did NIO, RARE, MCD Stocks Fall To 52-Week Lows? (Stocktwits)
Sep-03-26 05:19PM	IONS Edges Up After-Hours On FDAs Green Light For Neurology Drug After Being Dragged Down By Ultragenyxs Failed Trial (Stocktwits) -44.03%
05:18PM	Stocks to Watch Thursday Recap: Snowflake, Broadcom, HPE, Ultragenyx (The Wall Street Journal)
10:52AM	Ultragenyx mulls fate of rare disease programme on Phase III flop (Clinical Trials Arena)
10:34AM	Loading…
10:34AM	Inside Ultragenyx's Drug Flop: High Costs, Downgrades, and a Pipeline Play (Barrons.com)
09:31AM	Broadcom upgraded, Ultragenyx downgraded: Wall Street's top analyst calls (The Fly)
07:46AM	Ultragenyx Stock Sinks 47% on Drug Trial Failure. Why Wall Street Isn't Giving Up Yet. (Barrons.com)
07:00AM	Ultragenyx Shares Fall After Phase 3 Aspire Study Misses Primary Endpoint (InvestorsHub)
06:50AM	RARE Stock Heads For Record Low: Angelman Trial Miss Leads To Wall Street Downgrades This Analyst Sees Another Problem Ahead (Stocktwits)
05:45AM	Premarket movers: Snowflake, Five Below surge after strong earnings (Investing.com)
Sep-02-26 06:45PM	Why Did RARE Stock Slump 46% After-Hours? (Stocktwits)
04:01PM	Ultragenyx Announces Phase 3 Aspire results in Angelman Syndrome (GlobeNewswire)
Sep-01-26 04:05PM	Ultragenyx Announces the Publication of a Successful 96-Week Randomized, Placebo-Controlled Trial with Crossover Treatment of GENGLYCOS (also known as DTX401) AAV Gene Therapy in GSDIa in The Journal of Inherited Metabolic Disease (GlobeNewswire)
Aug-25-26 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-20-26 09:45AM	Drone Innovator Duke Robotics Receives $12 Price Target and Buy Rating From Wall Street Analyst (NASDAQ: DUKR) (FinanceWire)
08:48AM	Ultragenyxs Gene-Therapy Win Could Unlock A Long Revenue Tailwind, Says Wells Fargo This Analyst Sees 265% Upside For RARE Stock (Stocktwits)
07:13AM	Ultragenyx, after setbacks, nabs first gene therapy approval (BioPharma Dive)
05:32AM	Strategy stock surges on bitcoin bounce, and other early market movers (MarketWatch)
Aug-19-26 06:55PM	RARE Stock Jumps 6% After-Hours On First Gene Therapy Approval, New Priority Review Voucher (Stocktwits)
05:21PM	Loading…
05:21PM	Ultragenyx Announces U.S. FDA Approval of GENGLYCOS Gene Therapy, the First-Ever FDA-Approved Treatment Designed to Treat the Underlying Cause of Glycogen Storage Disease Type Ia (GSDIa) (GlobeNewswire)
Aug-18-26 07:44PM	RARE Stock Clocks Two Consecutive Days Of Losses Ahead Of Weekend FDA Decision On Gene Therapy (Stocktwits)
Aug-05-26 08:30AM	Ultragenyx Pharmaceutical Inc. Q2 2026 Earnings Call Summary (Moby)
01:01AM	Ultragenyx Pharmaceutical Inc (RARE) (Q2 2026) Earnings Call Highlights: Record Revenue and ... (GuruFocus.com)
Aug-04-26 04:55PM	Ultragenyx: Q2 Earnings Snapshot (Associated Press)
04:05PM	Ultragenyx Reports Second Quarter 2026 Financial Results and Corporate Update (GlobeNewswire)
Aug-03-26 05:26PM	MRNA, LNTH, BMY, CAPR, RARE Stocks In Focus These FDA Decisions Could Shape August Trading (Stocktwits)
Jul-28-26 04:05PM	Ultragenyx to Host Conference Call for Second Quarter 2026 Financial Results and Corporate Update (GlobeNewswire)
Jul-24-26 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-08-26 09:08AM	Ultragenyx Releases 2025 Impact Report Emphasizing Commitment to Rare Disease Patients, Innovation, and Global Impact (GlobeNewswire)
Jun-19-26 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-03-26 04:30PM	Ultragenyx to Participate at Goldman Sachs 47th Annual Global Healthcare Conference (GlobeNewswire)
May-22-26 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-06-26 04:30PM	Ultragenyx to Participate at Bank of America's 2026 Healthcare Conference (GlobeNewswire)
08:30AM	Ultragenyx Pharmaceutical Inc. Q1 2026 Earnings Call Summary (Moby)
May-05-26 04:07PM	Ultragenyx: Q1 Earnings Snapshot (Associated Press)
04:01PM	Ultragenyx Reports First Quarter 2026 Financial Results and Corporate Update (GlobeNewswire)
Apr-29-26 08:00AM	Ultragenyx to Host Conference Call for First Quarter 2026 Financial Results and Corporate Update (GlobeNewswire)
Apr-24-26 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-02-26 08:30AM	Ultragenyx Announces U.S. FDA Acceptance of BLA Resubmission for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA) (GlobeNewswire)
Mar-30-26 08:30AM	Ultragenyx Announces FDA Clearance of Investigational New Drug (IND) Application for UX016, a Sialic Acid Prodrug for the Treatment of GNE Myopathy (GlobeNewswire)
03:41AM	Ultragenyx Pharmaceutical Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RARE (PR Newswire)
Mar-24-26 09:36AM	Microsoft reinstated, Ralph Lauren upgraded: Wall Street's top analyst calls (The Fly) -8.73%
Mar-20-26 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-13-26 06:17AM	Evotec, Vistagen lay off staff; Immutep shares collapse on study failure (BioPharma Dive)
Mar-12-26 08:30AM	Ultragenyx Announces Positive 36-Week Data from Phase 3 Study of DTX301 AAV8 Gene Therapy for the Treatment of Ornithine Transcarbamylase (OTC) Deficiency (GlobeNewswire)
04:18AM	Ultragenyx Pharmaceutical Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RARE (PR Newswire)
Mar-11-26 09:00AM	LEVI & KORSINSKY, LLP: CEO AND CMO NAMED AS CONTROL PERSON DEFENDANTS IN ULTRAGENYX PHARMACEUTICAL SECURITIES ACTION (PR Newswire)
Mar-04-26 09:00AM	LEVI & KORSINSKY, LLP: RARE STOCK DECLINED OVER 42% FOLLOWING PHASE III STUDY FAILURE DISCLOSURE (PR Newswire)
Feb-25-26 09:00AM	LEVI & KORSINSKY, LLP: MANAGEMENT CONFIDENCE REPRESENTATIONS CHALLENGED IN ULTRAGENYX PHARMACEUTICAL SECURITIES ACTION (PR Newswire)
Feb-24-26 10:19AM	Ultragenyx Pharmaceutical Inc. (RARE): A Bull Case Theory (Insider Monkey)
Feb-23-26 04:30PM	Ultragenyx to Participate at Investor Conferences in March (GlobeNewswire)
08:30AM	Ultragenyx Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application (BLA) for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa) (GlobeNewswire)
Feb-20-26 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-16-26 12:23PM	Strong Rare Disease Pipeline Drives Favorable Sentiment for Ultragenyx (RARE) (Insider Monkey)
Feb-14-26 01:29AM	Ultragenyx (RARE) Announces Positive Long-Term Clinical Data for UX111 Gene Therapy in Sanfilippo Syndrome Type A (Insider Monkey)
Feb-13-26 01:21PM	Why Is Ultragenyx Stock Sinking Friday? (Benzinga) -12.68%
10:23AM	Ultragenyx Q4 Loss Wider Than Expected, Revenues Increase Y/Y (Zacks)
08:30AM	Ultragenyx Pharmaceutical Inc. Q4 2025 Earnings Call Summary (Moby)
05:08AM	Ultragenyx cuts jobs as it seeks path to profit in 2027 (BioPharma Dive)
12:02AM	Ultragenyx Pharmaceutical Inc (RARE) Q4 2025 Earnings Call Highlights: Strong Revenue Growth ... (GuruFocus.com)
Feb-12-26 08:14PM	Ultragenyx Pharmaceutical Q4 Earnings Call Highlights (MarketBeat)
06:00PM	Ultragenyx (RARE) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
05:15PM	Ultragenyx (RARE) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
04:18PM	Ultragenyx: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Ultragenyx Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Update (GlobeNewswire)
Feb-09-26 03:30AM	Ultragenyx Pharmaceutical Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RARE (PR Newswire)
Feb-07-26 03:33AM	Ultragenyx Pharmaceutical (RARE) Resubmits Biologics License Application for Gene Therapy Treatment (Insider Monkey)
Feb-06-26 07:40AM	Ultragenyx Pharmaceutical Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights RARE (Business Wire)
Feb-05-26 04:05PM	Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update (GlobeNewswire)
10:00AM	Ultragenyx (RARE) May Report Negative Earnings: Know the Trend Ahead of Q4 Release (Zacks)
Feb-03-26 12:58PM	Ultragenyx Says Gene Therapy Shows Lasting Benefits, Slows Brain Decline In Fatal Childhood Disorder (Benzinga)
08:00AM	Ultragenyx Announces Positive Longer-Term Data Demonstrating Treatment with UX111 Gene Therapy Results in Sustained, Significant Reductions in CSF-HS and Continued Meaningful Improvements in Clinical Function Across Multiple Developmental Domains in Children with Sanfilippo Syndrome (MPS IIIA) (GlobeNewswire)
Feb-02-26 11:03AM	Ultragenyx Pharmaceutical Resubmits UX111 BLA for Sanfilippo Syndrome (Zacks)
Jan-30-26 08:30AM	Ultragenyx Resubmits Biologics License Application for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA) to U.S. FDA (GlobeNewswire)
Jan-23-26 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
02:05PM	Ultragenyx Stock Declines After Missing Primary Endpoints on its Phase III Orbit and Cosmic Studies (PR Newswire)
Jan-21-26 04:58PM	Cathie Wood Has 13 Big Ideas For 2026: Here's The Ark Invest List And Stocks To Watch (Benzinga)
Jan-12-26 10:11AM	Morgan Stanley Trims Ultragenyx (RARE) PT to $50 While Betting on 2026 Biotech Recovery (Insider Monkey) +8.26%
07:30AM	Ultragenyx Provides Financial and Business Updates at J.P. Morgan Annual Healthcare Conference (GlobeNewswire)
Jan-09-26 03:16AM	Analysts Lower Ultragenyx (RARE) Target but Stay Bullish (Insider Monkey)
Jan-07-26 04:05PM	Ultragenyx to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +7.36%
Jan-05-26 03:56AM	Novo launches Wegovy pill; Argenx to swap CEOs (BioPharma Dive)
Dec-31-25 09:50AM	RARE Rises on Completion of Rolling Submission for AAV Gene Therapy (Zacks)
09:40AM	DigitalBridge downgraded, Commvault initiated: Wall Streets top analyst calls (TipRanks)
09:01AM	Ultragenyx (RARE) Moves 15.5% Higher: Will This Strength Last? (Zacks)
07:37AM	Ultragenyx (RARE) Rockets 15.5% on Bargain-Hunting After Steep Fall (Insider Monkey)
Dec-30-25 04:31PM	Stocks Fall Slightly in Thin Holiday Trade (Barchart) +15.52%
04:05PM	Ultragenyx Completes Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa) (GlobeNewswire)
03:58PM	Why Ultragenyx Pharmaceutical Stock Is Bouncing Back Today (Motley Fool)

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010 and is headquartered in Novato, CA.

Ph.D.Dr. Emil D. Kakkis M.D.

Executive VP of Corporate Strategy & CFOMr. Howard Horn

Chief Legal Officer & Executive VP of Corporate AffairsMs. Karah Herdman Parschauer J.D.

Executive VP & Chief Commercial OfficerMr. Erik Harris M.B.A.

Chief Medical Officer & Executive VPDr. Eric Crombez M.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Huizenga Theodore Alan	SVP, Chief Accounting Officer	Sep 15 '26	Sale	13.57	1,283	17,410	67,863	Sep 15 06:57 PM
THEODORE HUIZENGA	Officer	Sep 15 '26	Proposed Sale	13.61	1,283	17,462		Sep 15 04:33 PM
Huizenga Theodore Alan	SVP, Chief Accounting Officer	Sep 03 '26	Sale	13.99	161	2,252	69,146	Sep 08 12:29 PM
Parschauer Karah Herdman	EVP and Chief Legal Officer	Aug 03 '26	Sale	24.92	1,900	47,348	92,562	Aug 04 03:15 PM
Horn Howard	Chief Financial Officer	Aug 03 '26	Sale	24.92	4,696	117,024	96,295	Aug 04 03:13 PM
HOWARD HORN	Officer	Aug 03 '26	Proposed Sale	24.92	4,696	117,024		Aug 03 04:18 PM
Horn Howard	Chief Financial Officer	Jul 01 '26	Sale	33.13	4,698	155,645	100,991	Jul 06 03:37 PM
HOWARD HORN	Officer	Jul 01 '26	Proposed Sale	33.13	4,698	155,645		Jul 01 04:19 PM
Sanders Corazon (Corsee) D.	Director	Jun 15 '26	Sale	25.05	2,000	50,100	21,095	Jun 15 06:50 PM
Parschauer Karah Herdman	EVP and Chief Legal Officer	Jun 15 '26	Sale	24.62	1,899	46,753	94,462	Jun 15 06:46 PM
KARAH PARSCHAUER	Officer	Jun 15 '26	Proposed Sale	24.35	3,799	92,506		Jun 15 04:50 PM
CORAZON D. SANDERS	Director	Jun 15 '26	Proposed Sale	25.05	2,000	50,100		Jun 15 04:12 PM
Horn Howard	Chief Financial Officer	Jun 01 '26	Sale	23.77	4,653	110,602	105,689	Jun 01 07:11 PM
HOWARD HORN	Officer	Jun 01 '26	Proposed Sale	23.77	4,653	110,602		Jun 01 04:08 PM
SULIMAN SHEHNAAZ	Director	May 18 '26	Sale	25.12	5,740	144,189	27,951	May 18 06:41 PM
SHEHNAAZ SULIMAN	Director	May 18 '26	Proposed Sale	25.12	5,740	144,189		May 18 04:50 PM
Crombez Eric	EVP and Chief Medical Officer	May 05 '26	Sale	24.96	344	8,586	111,189	May 06 02:51 PM
Horn Howard	Chief Financial Officer	May 01 '26	Sale	24.90	4,683	116,607	110,342	May 04 05:35 PM
HOWARD HORN	Officer	May 01 '26	Proposed Sale	24.90	4,683	116,607		May 01 04:06 PM
Horn Howard	Chief Financial Officer	Apr 01 '26	Sale	20.97	4,683	98,203	80,351	Apr 02 06:19 PM
HOWARD HORN	Officer	Apr 01 '26	Proposed Sale	20.97	4,683	98,203		Apr 01 04:12 PM
Parschauer Karah Herdman	EVP and Chief Legal Officer	Mar 06 '26	Sale	21.40	6,018	128,785	70,328	Mar 10 04:51 PM
Parschauer Karah Herdman	EVP and Chief Legal Officer	Mar 10 '26	Sale	22.67	3,508	79,526	66,820	Mar 10 04:51 PM
KARAH PARSCHAUER	Officer	Mar 10 '26	Proposed Sale	22.67	3,508	79,526		Mar 10 04:42 PM
KARAH PARSCHAUER	Officer	Mar 06 '26	Proposed Sale	21.40	6,018	128,775		Mar 06 05:28 PM
Pinion John Richard	See Remarks	Mar 02 '26	Sale	22.80	10,029	228,661	110,026	Mar 03 07:09 PM
Harris Erik	EVP & Chief Commercial Officer	Mar 02 '26	Sale	22.80	10,539	240,289	89,515	Mar 03 07:08 PM
KAKKIS EMIL D	President & CEO	Mar 02 '26	Sale	22.80	54,404	1,240,411	658,994	Mar 03 07:06 PM
Parschauer Karah Herdman	EVP and Chief Legal Officer	Mar 02 '26	Sale	22.80	8,135	185,478	76,346	Mar 03 06:51 PM
Huizenga Theodore Alan	SVP, Chief Accounting Officer	Mar 02 '26	Sale	22.80	1,632	37,210	48,670	Mar 03 06:51 PM
Horn Howard	Chief Financial Officer	Mar 02 '26	Sale	22.70	8,409	190,914	86,669	Mar 03 06:50 PM
Horn Howard	Chief Financial Officer	Mar 03 '26	Sale	22.40	1,635	36,624	85,034	Mar 03 06:50 PM
Crombez Eric	EVP and Chief Medical Officer	Mar 02 '26	Sale	22.80	7,029	160,261	76,301	Mar 03 06:49 PM
HOWARD HORN	Officer	Mar 03 '26	Proposed Sale	22.40	1,635	36,624		Mar 03 04:41 PM
HOWARD HORN	Officer	Mar 02 '26	Proposed Sale	22.54	3,119	70,302		Mar 02 05:08 PM
Horn Howard	Chief Financial Officer	Feb 02 '26	Sale	23.56	3,061	72,117	88,935	Feb 03 12:00 PM
HOWARD HORN	Officer	Feb 02 '26	Proposed Sale	23.56	3,061	72,117		Feb 02 04:09 PM
Horn Howard	Chief Financial Officer	Jan 02 '26	Sale	22.84	3,150	71,946	91,996	Jan 05 04:07 PM
HOWARD HORN	Officer	Jan 02 '26	Proposed Sale	22.84	3,150	71,946		Jan 02 04:10 PM
Huizenga Theodore Alan	SVP, Chief Accounting Officer	Dec 29 '25	Sale	34.38	85	2,922	50,450	Dec 30 01:49 PM
Horn Howard	Chief Financial Officer	Dec 10 '25	Sale	36.38	3,081	112,087	95,146	Dec 11 12:10 PM
HOWARD HORN	Officer	Dec 10 '25	Proposed Sale	36.38	3,081	112,087		Dec 10 04:05 PM
Horn Howard	Chief Financial Officer	Oct 13 '25	Sale	31.51	7,942	250,252	98,227	Oct 14 12:15 PM

ONC BeOne Medicines Ltd ADR daily Stock Chart

Peers: REGN VRTX ALNY ARGX BIIB AMGN BMRN GILD ABBV LLY

| Held by: IBB FBT CGGO CGGE CGIE BBH CGNG CANC BGGG EMEQ

Index	-
Market Cap	37.68B
Enterprise Value	34.47B
Income	657.23M
Sales	6.14B
Book/sh	45.78
Cash/sh	50.44
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	0.00%
Employees	12000
IPO	Feb 03, 2016

P/E	63.50
Forward P/E	36.15
PEG	0.49
P/S	6.13
P/B	7.89
P/C	7.16
P/FCF	28.26
EV/EBITDA	31.89
EV/Sales	5.61
Quick Ratio	3.06
Current Ratio	3.40
Debt/Eq	0.40
LT Debt/Eq	0.34
Option/Short	Yes / Yes

EPS (ttm)	5.69
EPS next Y	10.00
EPS next Q	1.87
EPS this Y	176.29%
EPS next Y	37.57%
EPS next 5Y	73.16%
EPS past 3/5Y	- -
Sales past 3/5Y	55.88% 76.88%
EPS Y/Y TTM	449.53%
Sales Y/Y TTM	34.39%
EPS Q/Q	143.77%
Sales Q/Q	29.39%
Earnings	Aug 05 BMO
EPS/Sales Surpr.	23.45% 4.95%

Insider Own	0.53%
Insider Trans	-64.88%
Inst Own	33.30%
Inst Trans	2.01%
ROA	8.49%
ROE	14.70%
ROIC	9.50%
Gross Margin	86.76%
Oper. Margin	15.06%
Profit Margin	10.70%
SMA20	1.22%
SMA50	2.07%
SMA200	12.78%
Trades

Shs Outstand	104.17M
Shs Float	103.72M
Short Float	1.65%
Short Ratio	4.36
Short Interest	1.71M
52W High	385.22 -6.20%
52W Low	253.95 42.29%
Volatility	2.94% 2.12%
ATR (14)	9.10
RSI (14)	53.11
Beta	0.64
Rel Volume	0.46
Avg Volume	391.23K
Volume	22,508

Perf Week	-1.54%
Perf Month	-0.37%
Perf Quarter	16.95%
Perf Half Y	19.45%
Perf YTD	18.93%
Perf Year	5.08%
Perf 3Y	111.72%
Perf 5Y	4.03%
Perf 10Y	1040.58%
Recom	1.28
Target Price	436.06
Prev Close	358.07
Price	361.33
Change %	0.91%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-13-26	Upgrade	Jefferies	Hold → Buy	$380
Mar-27-26	Initiated	Wolfe Research	Outperform	$340
Mar-16-26	Downgrade	Jefferies	Buy → Hold	$290
Nov-24-25	Initiated	Truist	Buy
Sep-18-25	Initiated	Barclays	Overweight	$385
Apr-07-25	Initiated	RBC Capital Mkts	Outperform	$312
Mar-03-25	Upgrade	BofA Securities	Neutral → Buy	$207 → $320
Dec-03-24	Resumed	Morgan Stanley	Overweight	$300
Sep-18-24	Initiated	JMP Securities	Mkt Outperform	$288
Feb-06-24	Resumed	JP Morgan	Overweight	$185
Sep-12-23	Initiated	Macquarie	Outperform	$259
Aug-17-23	Initiated	Jefferies	Buy	$287
Jul-17-23	Initiated	Citigroup	Buy	$275
Jun-30-23	Downgrade	Bernstein	Outperform → Mkt Perform	$335 → $196
Jan-12-23	Initiated	Daiwa Securities	Buy	$308
Oct-13-22	Upgrade	SVB Leerink	Mkt Perform → Outperform	$177 → $200
Oct-13-22	Upgrade	Guggenheim	Neutral → Buy	$205
Aug-09-22	Resumed	JP Morgan	Overweight	$296
Mar-17-22	Downgrade	SVB Leerink	Outperform → Mkt Perform	$300 → $177
Feb-07-22	Initiated	Deutsche Bank	Buy

Show Previous Ratings

Oct-01-26 12:49PM	Biotech Leader BeOne Medicines Poised To Hit Early Buy Points (Investor's Business Daily)
Aug-31-26 03:00PM	BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines (Business Wire)
Aug-27-26 04:54PM	Generative "AI" Macro Data Shows U.S. Impacts (Zacks)
Aug-25-26 10:40AM	BeOne Medicines Announces U.S. FDA Approval for TEVIMBRA-Based Regimen for First-Line HER2+ GEA (Business Wire)
Aug-12-26 09:04PM	BeOne Medicines Ltd (ONC) (Q2 2026) Earnings Call Highlights: Revenue Surges 30% to $1. ... (GuruFocus.com)
08:41AM	Loading…
Jul-23-26 08:41AM	BeOne Medicines expands New Jersey campus with additional $300 million investment (NASDAQ:ONC) (InvestorsHub)
06:00AM	BeOne Medicines Expands U.S. Manufacturing with Total Investment of More Than $1 Billion to Advance Innovative Cancer Medicines (Business Wire)
Jun-30-26 06:00AM	BeOne Medicines Announces Positive Phase 3 Results for BRUKINSA in Frontline Mantle Cell Lymphoma (Business Wire)
Jun-11-26 07:24AM	BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit (Business Wire)
Jun-01-26 06:00AM	BeOne Medicines Highlights Accelerating Solid Tumor Pipeline with New Data at ASCO 2026 (Business Wire)
May-29-26 06:00AM	BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 2026 (Business Wire)
May-27-26 05:00PM	BeOne Medicines Announces Phase 3 HERIZON-GEA Data Published in NEJM and Presented at ASCO 2026 (Business Wire)
May-26-26 06:01AM	BeOne Medicines to Present at the Goldman Sachs 47th Annual Global Healthcare Conference (Business Wire)
May-21-26 06:00AM	BeOne Medicines Sets the Pace in Oncology at ASCO and EHA 2026 with 60+ Abstracts (Business Wire)
May-13-26 01:27PM	BeOne Medicines BEQALZI (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell Lymphoma (Business Wire)
06:00AM	Loading…
May-06-26 06:00AM	BeOne Medicines Announces First Quarter 2026 Financial Results and Business Updates (Business Wire) +5.32%
May-04-26 09:43AM	AMD downgraded, Airbnb upgraded: Wall Street's top analyst calls (The Fly)
Apr-29-26 06:00AM	U.S. FDA Grants Priority Review to BeOne Medicines TEVIMBRA in First-Line HER2+ GEA (Business Wire)
Apr-22-26 06:01AM	BeOne Medicines to Announce First Quarter 2026 Financial Results on May 6 (Business Wire)
Mar-03-26 08:02PM	BeOne Medicines Ltd (ONC) Q4 2025 Earnings Call Highlights: Record Growth and Strategic Expansion (GuruFocus.com) -5.51%
Mar-01-26 09:59AM	BeOne Medicines (ONC) Reports $1.5B Revenue for Q4, $1.1B from Lymphoma Treatment (Insider Monkey)
Feb-26-26 09:30AM	Here's What Key Metrics Tell Us About BeOne Medicines Ltd. - Sponsored ADR (ONC) Q4 Earnings (Zacks) -8.48%
06:00AM	BeOne Medicines Announces Fourth Quarter and Full Year 2025 Financial Results, Highlighting Global Success of BRUKINSA and Foundational Oncology Leadership (Business Wire)
Feb-17-26 06:00AM	BeOne Medicines to Present at Upcoming Investor Conferences (Business Wire)
Feb-13-26 05:19AM	Bernstein Remains a Buy on BeOne Medicines AG (ONC) (Insider Monkey)
Feb-11-26 06:00AM	BeOne Medicines to Announce Fourth Quarter and Full Year 2025 Financial Results on February 26 (Business Wire)
Feb-02-26 03:10AM	3 Stocks to Buy in February (Motley Fool)
Jan-31-26 09:36AM	Wall Street Bullish on BeOne Medicines AG (ONC) amid Robust Pipeline Development (Insider Monkey)
Jan-30-26 02:07AM	Citizens Highlights BeOne Medicines' (ONC) $3.8B Revenue Potential for 2025 (Insider Monkey)
Jan-29-26 12:28PM	FDA Accepts Summit's Lung Cancer Drug Application, Review Underway (Benzinga)
06:00AM	Loading…
Jan-13-26 06:00AM	BeOne Medicines Highlights Global Oncology Leadership at 44th Annual J.P. Morgan Healthcare Conference (Business Wire) +5.11%
Jan-07-26 10:22AM	Is the Options Market Predicting a Spike in BeOne Medicines Stock? (Zacks)
Jan-06-26 01:30PM	ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA (Business Wire)
Dec-31-25 08:51AM	Strong Momentum Lifted BeOne Medicines AG (ONC) in Q3 (Insider Monkey)
Dec-23-25 06:01AM	BeOne Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-18-25 06:00AM	BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma (Business Wire)
Dec-14-25 03:30AM	Kymera Had a Big Week. This Secretive Hedge Fund Bought $172 Million of Its Stock. (Barrons.com)
Dec-08-25 08:00AM	BRUKINSA Delivers Landmark 74% 6-Year PFS in Patients with Treatment-Nave Chronic Lymphocytic Leukemia (Business Wire)
Dec-07-25 06:00PM	Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies (Business Wire)
Nov-28-25 10:07AM	Biotechs Are On A Big Run, And Two Stocks Have Buy Points (Investor's Business Daily)
Nov-26-25 04:11PM	Medicare Slashes Ozempic's Price Tag 71%; Why Novo Nordisk Rallied (Investor's Business Daily)
Nov-21-25 12:59PM	This Pharma Stock Owned By Top Fund Flirts With Entry As Earnings Surge 452% (Investor's Business Daily)
Nov-20-25 06:00AM	BeOne Medicines Showcases Leadership in B-cell Malignancies at ASH 2025 (Business Wire)
Nov-17-25 08:10AM	Jazz Pharmaceuticals and Zymeworks Report Positive Cancer Treatment Results. The Stocks Soar. (Barrons.com)
06:00AM	Positive Phase 3 Results Support ZIIHERA as HER2-Targeted Therapy-of-Choice and Combination with TEVIMBRA and Chemotherapy as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma (Business Wire)
Nov-12-25 04:39PM	Stock Market Today: Dow Hits New Highs; Lilly, Barrick, Goldman Break Out (Live Coverage) (Investor's Business Daily) +9.84%
04:30PM	BeOne, IBD Stock Of The Day, Breaks Out As It Takes On Cancer Giants J&J, AbbVie (Investor's Business Daily)
01:19PM	BeOne Medicines Stock Earns Relative Strength Rating Upgrade (Investor's Business Daily)
12:55PM	IBD Stock Of The Day BeOne Breaks Out As It Takes On Cancer Giants J&J, AbbVie (Investor's Business Daily)
10:31AM	Stock Market Today: Dow Rises But Nasdaq Cools Again As Nvidia, AMD Rally (Live Coverage) (Investor's Business Daily)
Nov-11-25 12:07PM	Biotech Leader BeOne Medicines Eyes New Buy Point As Cancer Drug Sales Surge (Investor's Business Daily)
Nov-10-25 08:03PM	BeOne Medicines Ltd (ONC) Q3 2025 Earnings Call Highlights: Record Revenue and Strategic ... (GuruFocus.com)
Nov-06-25 11:30AM	BeOne Medicines Ltd. - Sponsored ADR (ONC) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
06:00AM	BeOne Medicines Announces Third Quarter 2025 Financial Results and Business Updates (Business Wire)
Oct-28-25 06:01AM	BeOne Medicines to Present at Upcoming Investor Conferences (Business Wire)
Oct-21-25 01:41PM	SMMT's Q3 Loss Wider Than Expected, Stock Down on Study Amendments (Zacks)
Oct-20-25 06:00AM	BeOne Medicines Presents New Data on TEVIMBRA in Lung Cancer at ESMO 2025 (Business Wire)
Oct-13-25 06:00AM	BeOne Medicines Sonrotoclax Granted Breakthrough Therapy Designation by U.S. FDA (Business Wire)
Oct-03-25 04:21PM	How BeOne Medicines, An IBD 50 Stock, Is Taking On Big Names In Cancer Treatment (Investor's Business Daily)
Oct-02-25 01:35AM	BeOne Medicines (ONC) Gains Barclays Overweight Rating Ahead of Key 2025 Data Readouts (Insider Monkey)
Sep-29-25 10:35AM	Here's Why BeOne Medicines Ltd. (ONC) Declined in Q2 (Insider Monkey)
Sep-18-25 03:00AM	China's Young Consumers Set the Global Trend. What They're Buying Now. (Barrons.com)
Sep-14-25 01:16AM	Citizens JMP Maintains a Buy Rating on BeOne Medicines (ONC) (Insider Monkey)
Sep-12-25 01:01AM	BeOne Medicines (ONC) Reports Positive Phase 1/2 Results for Sonrotoclax in MCL (Insider Monkey)
Sep-10-25 03:55PM	China-Tied Biotechs Zai Labs, BeOne Plunge On Rumored Executive Order (Investor's Business Daily) -10.59%
Aug-29-25 06:00AM	BeOne Medicines Announces Positive Topline Results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL) (Business Wire)
Aug-28-25 04:55AM	BeOne Medicines Ltd. (ONC) Unveils Promising Breast Cancer Therapies at ASCO 2025 (Insider Monkey)
Aug-27-25 06:00AM	European Commission Approves TEVIMBRA as Neoadjuvant/Adjuvant NSCLC Treatment Ahead of Late-Breaking Data Presentation at WCLC 2025 (Business Wire)
Aug-26-25 06:01AM	BeOne to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference (Business Wire)
Aug-21-25 06:00AM	European Commission Approves Tablet Formulation of BeOne Medicines BRUKINSA for All Approved Indications (Business Wire)
Aug-15-25 12:55PM	This Medical Stock With Blockbuster Cancer Drug Clears Entry Amid 923% Earnings Growth (Investor's Business Daily)
10:04AM	This Eye Treatment Stock Sees Sales Spike 152% As Biotech Leaders Shine (Investor's Business Daily)
Aug-08-25 12:44PM	Hims Stock Gets Booted Off IBD 50 While Other Volatile Names Hang On (Investor's Business Daily)
Aug-06-25 11:30AM	BeOne Medicines Ltd. - Sponsored ADR (ONC) Reports Q2 Earnings: What Key Metrics Have to Say (Zacks)
06:00AM	BeOne Medicines Announces Second Quarter 2025 Financial Results and Business Updates (Business Wire)
Jul-31-25 06:00AM	BeOne Medicines Receives PRIME Designation from the European Medicines Agency for BGB-16673 in Waldenstroms Macroglobulinemia (Business Wire)
Jul-28-25 06:00AM	BeOne Medicines Receives Positive CHMP Opinion for TEVIMBRA in Neoadjuvant/Adjuvant NSCLC Treatment (Business Wire)
Jul-25-25 10:44PM	BeOne Medicines Ltd. (ONC) Wins EU Nod for Tevimbra (Insider Monkey)
10:06AM	Stevanato (STVN) Soars 10.0%: Is Further Upside Left in the Stock? (Zacks)
Jul-18-25 03:43PM	The S&P 500 and Nasdaq Are Joined By These Stocks Hitting New Highs (Investor's Business Daily)
10:06AM	BeOne Medicines Ltd. - Sponsored ADR (ONC) Surges 4.0%: Is This an Indication of Further Gains? (Zacks)
Jul-16-25 12:58PM	Looming Tariffs Don't Scare This Swiss Cancer Treatment Stock (Investor's Business Daily)
06:00AM	BeOne Medicines to Announce Second Quarter 2025 Financial Results on August 6 (Business Wire)
Jul-10-25 06:00AM	European Commission Approves TEVIMBRA in Combination with Chemotherapy as a First-Line Treatment for Nasopharyngeal Carcinoma (Business Wire)
Jun-28-25 08:35AM	BeOne Medicines price target raised to $330 from $313 at Morgan Stanley (TipRanks)
Jun-26-25 06:00AM	BeOne Medicines Showcases Groundbreaking Oncology Pipeline at R&D Day (Business Wire)
Jun-25-25 06:00AM	BeOne Medicines Receives Positive CHMP Opinion for Tablet Formulation of BRUKINSA (Business Wire)
Jun-12-25 06:00AM	BeOne Medicines Showcases Breakthrough Data in CLL and MCL at EHA 2025 (Business Wire) +5.38%
Jun-11-25 04:05PM	U.S. FDA Approves Tablet Formulation of BeOnes BRUKINSA for All Approved Indications (Business Wire)
06:01AM	BeOne Medicines to Host Investor R&D Day Webcast on June 26, 2025 (Business Wire)
Jun-05-25 02:03PM	Cancer Stock Vaults 40% As Clinical Trial Shows 'Promise'; Sales Reach $1 Billion, Earnings To Triple (Investor's Business Daily)
Jun-02-25 06:00AM	BeOne Medicines Unveils Promising Clinical Data for Two Novel Breast Cancer Therapies at ASCO 2025 (Business Wire)
May-31-25 08:00AM	BeOne Medicines Presents New SEQUOIA Study Results Reinforcing BRUKINSAs Differentiated Profile with or without Venetoclax in Frontline CLL at ASCO 2025 (Business Wire)
May-27-25 08:30AM	BeOne Medicines Launches Following Redomiciliation to Switzerland, Marking a New Chapter in Global Oncology (Business Wire)
06:00AM	BeiGene Receives Positive CHMP Opinion for TEVIMBRA as a First-Line Treatment for Nasopharyngeal Cancer (Business Wire)
May-22-25 06:00AM	BeiGene Presents Pioneering Cancer Research at ASCO 2025 Redefining Treatment Across Hematology and Solid Tumors (Business Wire)
May-14-25 04:05PM	BeiGene Showcases Strength of Hematology Portfolio at EHA 2025 with New Data Highlighting BRUKINSAs Leadership and Next-Generation Innovation (Business Wire)
May-13-25 06:01AM	BeiGene to Present at the RBC Capital Markets Global Healthcare Conference (Business Wire)
May-12-25 07:33AM	Trumps Plan to Cut Drug Prices Hits Pfizer, Other Pharma Stocks (The Wall Street Journal)
12:05AM	Trump Drug Plan Hits Pharma Stocks (The Wall Street Journal)

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Co-FounderMr. John V. Oyler

President and Global Head of Research & DevelopmentMr. Wang Lai Ph.D.

Co-Chairman of Scientific Advisory BoardDr. Xiaodong Wang Ph.D.

Chief Financial OfficerMr. Aaron Rosenberg

General CounselMr. Chan Lee

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lee Chan Henry	SVP, General Counsel	Sep 30 '26	Sale	375.00	1,115	418,125	0	Oct 02 04:53 PM
Wang Xiaodong	Chair, Scientific Advisory Brd	Sep 28 '26	Option Exercise	36.90	31,028	1,144,933	31,028	Sep 30 05:11 PM
Wang Xiaodong	Chair, Scientific Advisory Brd	Sep 28 '26	Sale	364.79	31,028	11,318,558	0	Sep 30 05:11 PM
CHAN LEE	Officer	Sep 30 '26	Proposed Sale	365.27	1,115	407,276		Sep 30 04:20 PM
Wang Xiaodong	Chair, Scientific Advisory Brd	Sep 08 '26	Option Exercise	36.90	31,027	1,144,896	31,027	Sep 10 04:49 PM
Wang Xiaodong	Chair, Scientific Advisory Brd	Sep 08 '26	Sale	349.10	38,287	13,366,092	0	Sep 10 04:49 PM
XIAODONG WANG	Director	Sep 08 '26	Proposed Sale	358.26	131,370	47,064,616		Sep 08 04:26 PM
Ball Titus B.	Principal Accounting Officer	Sep 01 '26	Sale	355.86	132	46,974	0	Sep 03 05:17 PM
TITUS BENJAMIN BALL	Officer	Sep 01 '26	Proposed Sale	355.86	132	46,974		Sep 01 04:14 PM
Wu Xiaobin	President and COO	Aug 25 '26	Sale	380.00	280	106,400	0	Aug 27 05:12 PM
XIAOBIN WU	Officer	Aug 25 '26	Proposed Sale	371.98	15,000	5,579,700		Aug 25 04:44 PM
CORAZON D. SANDERS	Former Director	Aug 25 '26	Proposed Sale	380.00	2,075	788,500		Aug 25 04:01 PM
Lee Chan Henry	SVP, General Counsel	Aug 11 '26	Option Exercise	191.37	2,666	510,190	2,666	Aug 13 08:54 PM
Lee Chan Henry	SVP, General Counsel	Aug 11 '26	Sale	360.00	2,666	959,760	0	Aug 13 08:54 PM
OYLER JOHN	Chief Executive Officer	Aug 10 '26	Sale	357.87	115,011	41,159,461	125,799	Aug 12 05:53 PM
OYLER JOHN	Chief Executive Officer	Aug 11 '26	Sale	361.90	70,907	25,661,417	54,892	Aug 12 05:53 PM
OYLER JOHN	Chief Executive Officer	Aug 12 '26	Sale	358.15	54,892	19,659,594	0	Aug 12 05:53 PM
CHAN LEE	Officer	Aug 11 '26	Proposed Sale	359.00	2,002	718,718		Aug 11 04:31 PM
JOHN V OYLER	Director	Aug 10 '26	Proposed Sale	348.27	240,810	83,866,899		Aug 10 04:36 PM
Rosenberg Aaron	Chief Financial Officer	Aug 03 '26	Sale	312.71	1,157	361,811	0	Aug 05 05:15 PM
Lee Chan Henry	SVP, General Counsel	Jul 30 '26	Sale	323.69	1,044	337,932	0	Aug 03 05:18 PM
AARON ROSENBERG	Officer	Aug 03 '26	Proposed Sale	312.72	1,157	361,811		Aug 03 04:50 PM
CHAN LEE	Officer	Jul 30 '26	Proposed Sale	323.69	1,044	337,932		Jul 30 05:34 PM
Lee Chan Henry	SVP, General Counsel	Jul 22 '26	Option Exercise	191.58	1,669	319,740	1,669	Jul 24 04:51 PM
Lee Chan Henry	SVP, General Counsel	Jul 22 '26	Sale	325.00	1,669	542,425	0	Jul 24 04:51 PM
OYLER JOHN	Chief Executive Officer	Jul 20 '26	Option Exercise	119.96	33,990	4,077,440	33,990	Jul 22 05:03 PM
OYLER JOHN	Chief Executive Officer	Jul 21 '26	Sale	317.67	61,397	19,504,058	0	Jul 22 05:03 PM
OYLER JOHN	Chief Executive Officer	Jul 20 '26	Sale	312.25	48,316	15,086,797	0	Jul 22 05:03 PM
CHAN LEE	Officer	Jul 22 '26	Proposed Sale	318.69	2,001	637,689		Jul 22 04:29 PM
OYLER JOHN	Chief Executive Officer	Jul 17 '26	Option Exercise	119.96	64,628	7,752,775	64,628	Jul 17 05:36 PM
OYLER JOHN	Chief Executive Officer	Jul 17 '26	Sale	312.00	64,628	20,163,907	0	Jul 17 05:36 PM
OYLER JOHN	Chief Executive Officer	Jul 16 '26	Option Exercise	143.38	166,597	23,887,477	166,597	Jul 17 05:31 PM
OYLER JOHN	Chief Executive Officer	Jul 15 '26	Option Exercise	148.00	116,557	17,250,520	116,557	Jul 17 05:31 PM
OYLER JOHN	Chief Executive Officer	Jul 16 '26	Sale	318.09	166,597	52,992,224	0	Jul 17 05:31 PM
OYLER JOHN	Chief Executive Officer	Jul 15 '26	Sale	311.95	116,557	36,359,374	0	Jul 17 05:31 PM
OYLER JOHN	Chief Executive Officer	Jul 14 '26	Option Exercise	54.06	133,600	7,222,959	133,600	Jul 14 09:26 PM
OYLER JOHN	Chief Executive Officer	Jul 14 '26	Sale	305.95	145,861	44,626,424	0	Jul 14 09:26 PM
OYLER JOHN	Chief Executive Officer	Jul 13 '26	Option Exercise	36.90	48,520	1,790,388	48,520	Jul 14 09:25 PM
OYLER JOHN	Chief Executive Officer	Jul 10 '26	Option Exercise	36.90	11,698	431,656	11,698	Jul 14 09:25 PM
OYLER JOHN	Chief Executive Officer	Jul 13 '26	Sale	304.35	48,520	14,766,883	0	Jul 14 09:25 PM
OYLER JOHN	Chief Executive Officer	Jul 10 '26	Sale	298.34	11,698	3,489,925	0	Jul 14 09:25 PM
JOHN V OYLER	Director	Jul 14 '26	Proposed Sale	303.96	513,574	156,105,953		Jul 14 04:48 PM
Lee Chan Henry	SVP, General Counsel	Jul 08 '26	Option Exercise	191.56	664	127,196	664	Jul 10 04:44 PM
Lee Chan Henry	SVP, General Counsel	Jul 08 '26	Sale	302.46	664	200,833	0	Jul 10 04:44 PM
JOHN V OYLER	Director	Jul 10 '26	Proposed Sale	302.83	150,000	45,424,500		Jul 10 04:36 PM
PAN-OYLER FOUNDATION	Director	Jul 10 '26	Proposed Sale	302.83	49,541	15,002,501		Jul 10 04:35 PM
Wu Xiaobin	President and COO	Jun 23 '26	Sale	276.26	1,292	356,927	0	Jun 25 05:15 PM
OYLER JOHN	Chief Executive Officer	Jun 23 '26	Sale	273.78	3,410	933,592	0	Jun 25 05:15 PM
Wang Lai	President, Global Head of R&D	Jun 23 '26	Sale	276.74	1,068	295,553	0	Jun 25 05:14 PM
LAI WANG	Officer	Jun 23 '26	Proposed Sale	276.73	1,068	295,553		Jun 23 04:24 PM
XIAOBIN WU	Officer	Jun 23 '26	Proposed Sale	276.26	1,292	356,927		Jun 23 04:21 PM
JOHN OYLER	Officer	Jun 23 '26	Proposed Sale	273.78	3,410	933,592		Jun 23 04:13 PM
Wu Xiaobin	President and COO	Jun 16 '26	Sale	266.76	1,357	361,997	0	Jun 18 05:19 PM
OYLER JOHN	Chief Executive Officer	Jun 16 '26	Sale	265.55	3,693	980,686	0	Jun 18 05:19 PM
Lee Chan Henry	SVP, General Counsel	Jun 16 '26	Sale	265.98	590	156,925	0	Jun 18 05:19 PM
Wang Lai	President, Global Head of R&D	Jun 16 '26	Sale	265.39	1,169	310,236	0	Jun 18 05:19 PM
CHAN LEE	Officer	Jun 16 '26	Proposed Sale	265.98	590	156,925		Jun 16 04:15 PM
LAI WANG	Officer	Jun 16 '26	Proposed Sale	265.39	1,169	310,236		Jun 16 04:14 PM
XIAOBIN WU	Officer	Jun 16 '26	Proposed Sale	266.76	1,357	361,997		Jun 16 04:12 PM
JOHN OYLER	Officer	Jun 16 '26	Proposed Sale	265.55	3,693	980,686		Jun 16 04:11 PM
Ball Titus B.	Principal Accounting Officer	Jun 11 '26	Sale	257.20	169	43,467	0	Jun 15 05:55 PM
Wang Lai	President, Global Head of R&D	Jun 11 '26	Sale	261.00	756	197,318	0	Jun 15 05:55 PM
Rosenberg Aaron	Chief Financial Officer	Jun 11 '26	Sale	257.74	631	162,637	0	Jun 15 05:55 PM
Wu Xiaobin	President and COO	Jun 11 '26	Sale	261.20	626	163,512	0	Jun 15 05:55 PM
Lee Chan Henry	SVP, General Counsel	Jun 11 '26	Sale	257.63	428	110,268	0	Jun 15 05:55 PM
OYLER JOHN	Chief Executive Officer	Jun 11 '26	Sale	257.24	1,949	501,355	0	Jun 15 05:55 PM
CORAZON D. SANDERS	Director	Jun 15 '26	Proposed Sale	265.50	945	250,894		Jun 15 04:21 PM
XIAOBIN WU	Officer	Jun 11 '26	Proposed Sale	261.20	626	163,512		Jun 11 04:32 PM
LAI WANG	Officer	Jun 11 '26	Proposed Sale	261.41	756	197,630		Jun 11 04:29 PM
AARON ROSENBERG	Officer	Jun 11 '26	Proposed Sale	257.74	631	162,637		Jun 11 04:25 PM
TITUS BENJAMIN BALL	Officer	Jun 11 '26	Proposed Sale	257.20	169	43,467		Jun 11 04:24 PM
CHAN LEE	Officer	Jun 11 '26	Proposed Sale	257.63	428	110,268		Jun 11 04:23 PM
JOHN OYLER	Officer	Jun 11 '26	Proposed Sale	257.24	1,949	501,355		Jun 11 04:23 PM
Ball Titus B.	Principal Accounting Officer	Jun 08 '26	Sale	271.33	136	36,901	0	Jun 10 05:27 PM
Lee Chan Henry	SVP, General Counsel	Jun 08 '26	Sale	270.42	871	235,539	0	Jun 10 05:26 PM
Wang Lai	President, Global Head of R&D	Jun 08 '26	Sale	269.38	1,367	368,247	0	Jun 10 05:25 PM
Wu Xiaobin	President and COO	Jun 08 '26	Sale	269.37	1,484	399,738	0	Jun 10 05:23 PM
OYLER JOHN	Chief Executive Officer	Jun 08 '26	Sale	270.56	4,940	1,336,548	0	Jun 10 05:22 PM
TITUS BENJAMIN BALL	Officer	Jun 08 '26	Proposed Sale	271.33	136	36,901		Jun 08 04:31 PM
CHAN LEE	Officer	Jun 08 '26	Proposed Sale	270.42	871	235,539		Jun 08 04:29 PM
LAI WANG	Officer	Jun 08 '26	Proposed Sale	269.38	1,367	368,247		Jun 08 04:28 PM
XIAOBIN WU	Officer	Jun 08 '26	Proposed Sale	269.37	1,484	399,738		Jun 08 04:23 PM
JOHN OYLER	Officer	Jun 08 '26	Proposed Sale	270.56	4,940	1,336,548		Jun 08 04:18 PM
Yi Qingqing	Director	Jun 01 '26	Sale	279.13	235	65,596	0	Jun 03 04:10 PM
QINGQING YI	Director	Jun 01 '26	Proposed Sale	279.13	235	65,596		Jun 01 04:27 PM
Riva Alessandro	Director	May 22 '26	Sale	309.51	212	65,617	0	May 27 05:29 PM
Dugan Margaret	Director	May 22 '26	Sale	309.60	212	65,636	0	May 27 05:26 PM
Sanders Corazon (Corsee) D.	Director	May 22 '26	Sale	309.59	212	65,633	0	May 27 05:26 PM
BAKER BROS. ADVISORS LP	Director	May 22 '26	Sale	23.82	10,998	261,981	142,566	May 27 04:54 PM
MICHAEL GOLLER	Director	May 22 '26	Proposed Sale	310.07	211	65,424		May 22 04:28 PM
RANJEEV KRISHANA	Director	May 22 '26	Proposed Sale	309.28	212	65,567		May 22 04:25 PM
ALESSANDRO RIVA	Director	May 22 '26	Proposed Sale	309.51	212	65,617		May 22 04:22 PM
MARGARET DUGAN	Director	May 22 '26	Proposed Sale	309.60	212	65,636		May 22 04:20 PM
CORAZON D. SANDERS	Director	May 22 '26	Proposed Sale	309.59	212	65,633		May 22 04:18 PM
Lee Chan Henry	SVP, General Counsel	May 13 '26	Option Exercise	191.56	332	63,598	332	May 15 04:39 PM
Lee Chan Henry	SVP, General Counsel	May 13 '26	Sale	310.72	332	103,159	0	May 15 04:39 PM
CHAN LEE	Officer	May 13 '26	Proposed Sale	315.07	1,328	418,413		May 13 04:27 PM
Lee Chan Henry	SVP, General Counsel	Apr 08 '26	Option Exercise	191.56	332	63,598	332	Apr 10 05:40 PM
Lee Chan Henry	SVP, General Counsel	Apr 08 '26	Sale	311.59	332	103,448	0	Apr 10 05:40 PM
Lee Chan Henry	SVP, General Counsel	Mar 11 '26	Option Exercise	191.64	341	65,348	341	Mar 13 05:26 PM

LEGN

Legend Biotech Corp ADR

RARE

Ultragenyx Pharmaceutical Inc

ONC

BeOne Medicines Ltd ADR

Upgrade your Finviz experience